Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors  DOYLESTOWN, Pa., March  30, 2026  (GLOBE NEWSWIRE) -- Aprea

APRE

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Aprea secures $30 million in oversubscribed private placement

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors  DOYLESTOWN, Pa., March  30, 2026  (GLOBE NEWSWIRE) -- Aprea</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Aprea Therapeutics has successfully raised approximately $30 million through an oversubscribed private placement financing. This funding is anticipated to enhance their research and development efforts for biomarker-defined cancer treatments, extending their cash runway into early 2028.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Aprea secured $30 million from an oversubscribed private placement financing.</li><li>The financing includes pre-funded warrants and traditional warrants for common stock.</li><li>Funds will support general corporate purposes and R&amp;D activities.</li><li>Company plans to enhance Phase 1 trial enrollment for APR-1051.</li><li>Projected cash runway is extended into Q1 2028 with new capital.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Soleus Capital (N/A)</strong>: Led the private placement financing for Aprea.</li><li><strong>Vestal Point Capital (N/A)</strong>: Participated in Aprea&#039;s recent funding round.</li><li><strong>Squadron Capital Management (N/A)</strong>: Actively involved in supporting Aprea&#039;s financing efforts.</li><li><strong>Oppenheimer &amp; Co. Inc. (N/A)</strong>: Acting as the lead placement agent for the offering.</li><li><strong>Maxim Group LLC (N/A)</strong>: Co-lead placement agent for Aprea&#039;s financing.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls into &#039;Corporate Developments&#039; as it highlights Aprea&#039;s strategic financing to bolster capital for R&amp;D. This is crucial for a clinical-stage company focused on oncology treatments.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>The $30 million raised may boost investor confidence in Aprea&#039;s R&amp;D.</li><li>Enhanced funding could lead to accelerated trial timelines for APR-1051.</li><li>Successful patient enrollment in upcoming trials may drive stock price.</li><li>Improved cash runway reduces immediate financial risk for the company.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Private placement financing was led by Soleus Capital.</li><li>Offer consists of 37.2 million pre-funded warrants at $0.808 each.</li><li>Warrants have an exercise price of $0.683 and expire December 31, 2029.</li><li>Expected closure of the offering around March 31, 2026.</li><li>Company anticipates completing ACESOT-1051 trial dose escalation by Q2 2027.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying APRE based on strengthened financial position and growth prospects.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><ul type="disc"><li style="margin-bottom:12pt;"><em>Financing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors</em><br></br></li></ul>  <p align="justify">DOYLESTOWN, Pa., March  30, 2026  (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/APRE">APRE</a>) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $30 million to the Company before deducting placement agent fees and other private placement expenses (the "Offering").</p>  <p align="justify">The private placement was led by Soleus Capital with participation from other new investors, including Vestal Point Capital and Squadron Capital Management, existing investors and certain insiders of the Company.</p>  <p align="justify">In connection with the Offering the Company plans to sell (i) pre-funded warrants to purchase up to an aggregate of approximately 37.2 million shares of common stock ("Pre-Funded Warrants"), for a purchase price equal to $0.808, minus $0.001 per Pre-Funded Warrant, and (ii) warrants to purchase up to an aggregate of approximately 37.2 million shares of common stock. The warrants to be issued will have an exercise price of $0.683 per share, will be exercisable immediately upon issuance, and will expire on the earlier of (i) December 31, 2029, and (ii) 30 calendar days after the exercise of a holder's Pre-Funded Warrant on a pro rata basis.</p>  <p align="justify">The gross proceeds to the Company from the Offering are estimated to be approximately $30 million before deducting the placement agent's fees and other estimated Offering expenses. The Company intends to use the upfront net proceeds from the private placement for general corporate purposes and for research and development expenses. The Offering is expected to close on or about March 31, 2026, subject to the satisfaction of customary closing conditions.</p>  <p align="justify">In addition to the existing biomarker-enriched cohorts under evaluation in the ongoing ACESOT-1051 Phase 1 trial, Aprea plans to use commercially reasonable efforts to seek enrollment of at least 50 patients with uterine serous carcinoma (USC), as well as patients with Cyclin E-overexpressing, platinum-resistant ovarian cancer (PROC) in order to further assess APR-1051 in selected patient populations with high unmet medical need. The Company currently anticipates completing dose escalation of the ACESOT-1051 trial in the second quarter of 2027 and currently expects that the proceeds from the Offering will be sufficient to extend its cash runway into the first quarter of 2028, in each case, based on the Company's current business plans and assumptions.</p>  <p align="justify">Oppenheimer &amp; Co. Inc. is acting as the lead placement agent for the private placement. Maxim Group LLC is acting as co-lead placement agent for the private placement.</p>  <p align="justify">The offer and sale of the foregoing securities are being made in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder, and the securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the securities purchased in the private placement.</p>  <p align="justify">This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.</p>  <p align="justify"><strong>About Aprea</strong></p>  <p align="justify">Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea's technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The company's lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at <a href="https://www.globenewswire.com/Tracker?data=HgXBL-UWexdqhnbYdmEWBNnHosf0syrvGYzRDX9NaXJIUuCuuW754tZhIcAazKyA0E2e3nouzDPEUC2rHCUVIQ==" rel="nofollow" target="_blank">www.aprea.com</a>.</p>  <p align="justify">The Company may use, and intends to use, its investor relations website at <a href="https://ir.aprea.com/" title="https://ir.aprea.com/">https://ir.aprea.com/</a> as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.</p>  <p align="justify"><strong><em>Forward-Looking Statement</em></strong></p>  <p align="justify"><em>Certain information contained in this press release includes "forward-looking statements", within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as "future," "predicts," "believes," "potential," "continue," "anticipates," "estimates," "expects," "plans," "intends," "targeting," "confidence," "may," "could," "might," "likely," "will," "should" or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, the risk that the proposed private placement and the transactions described herein may not be completed in a timely manner or at all, the failure to realize the anticipated benefits of the private placement and related transactions, market and other conditions, as well as other factors described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.</em></p>  <p><strong>Investor Contact:</strong></p>  <p>Mike Moyer<br></br>LifeSci Advisors<br></br><a href="https://www.globenewswire.com/Tracker?data=OQD5Hf7zRHhqd6QAeaoDQ08SIhK2jcBQwNku2QVw4gqjyAi5AeZ56_PpGSH-piTjsLCwl0tIky9GIOQpcDnoEzpyPHxr8qLVYMnVp7UdLD5jvMzRW36YnZ1GTz0fJmHNicRdqMlVo3TsYxN6uvDjyRdfEY94DAFPQJr2sd1gzYipzdJpVUulgeOwmOUTtAbkwZyK4-DrW6tFefzXGOnaL8HtxKQNYdrCWz9QLqICRd_K1Jwd_BdUpY8A_RnyqgXgR_tA5Y-I2XsNL7XRzcrmWhGIygIhZ1HEk1C-rsqgvFi-AFijdDGNdXST9cjyv3yk" rel="nofollow" target="_blank">mmoyer@lifesciadvisors.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4MDY4NiM3NTA5OTIxIzIxODEyODA="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YWQwM2IzNDktNjMwMi00M2M4LWE0ZTQtZWQwNWZmOWI2MjFjLTExOTI4NDktMjAyNi0wMy0zMC1lbg==/tiny/Aprea-Therapeutics.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/c63a19fa-f624-43d3-852f-d5956983aef3"><img src="https://ml.globenewswire.com/media/c63a19fa-f624-43d3-852f-d5956983aef3/small/aprea-logo-jpg.jpg" border="0" width="150" height="37" alt="Primary Logo"></img></a></p>

Aprea Therapeutics has successfully raised approximately $30 million through an oversubscribed private placement financing. This funding is anticipated to enhance their research and development efforts for biomarker-defined cancer treatments, extending their cash runway into early 2028.

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News